Few topics around GLP-1 medications generate more anxiety than this one. "Ozempic and depression" trends on Google regularly. The FDA investigated. The European Medicines Agency investigated. Headlines oscillated between alarm and reassurance. If you're starting a GLP-1 and worrying about your mental health, you're not alone — and you deserve a careful, evidence-based answer rather than a clickbait one.
So here's what we actually know.
The clinical trial data: mostly reassuring
The most important study on this topic is a dedicated post-hoc analysis of the STEP 1, 2, 3, and 5 trials — the landmark semaglutide weight loss studies. Researchers specifically examined depression symptoms and suicidal ideation across thousands of participants taking semaglutide 2.4mg versus placebo.
The result: no increased risk of depression or suicidal thoughts. In fact, semaglutide was associated with a small, statistically significant reduction in depressive symptoms compared to placebo — though the reduction was modest enough that researchers described it as not clinically meaningful on its own (Wadden et al., 2024).
That's the gold-standard evidence. Controlled trials. Thousands of patients. Specific psychiatric assessments. No signal of harm.
A broader analysis looking at quality of life and physical functioning across the STEP trials found significant improvements in both measures — people felt better physically and psychologically on semaglutide compared to placebo (Rubino et al., 2024).
The post-marketing signals: more complicated
Clinical trials are controlled environments with carefully selected participants. The real world is messier.
Post-marketing surveillance databases — where doctors and patients voluntarily report adverse events — have shown some signals worth paying attention to. An analysis of the EudraVigilance database found that psychiatric events accounted for about 1.18% of total reports for GLP-1 medications. Of those psychiatric reports, depression was most common (50.3%), followed by anxiety (38.7%) and suicidal ideation (19.6%) (Tobaiqy et al., 2024).
A separate analysis of the WHO's VigiBase identified a disproportionality signal for suicidal ideation with semaglutide specifically (Schoretsanitis et al., 2024).
These reports need context. Disproportionality signals in pharmacovigilance databases don't prove causation. People taking GLP-1 medications for obesity already have higher baseline rates of depression and anxiety. Rapid weight loss itself — by any method — can trigger mood changes. And the sheer volume of GLP-1 prescriptions means even rare events generate numerous reports.
But they also shouldn't be dismissed entirely. They mean monitoring matters.
The emerging positive picture
Perhaps the most interesting recent finding comes from a 2026 study in The Lancet Psychiatry, which looked at people with existing depression or anxiety who started semaglutide. Rather than worsening, these patients showed a lower risk of their mental illness deteriorating — with an adjusted hazard ratio of 0.58, meaning their risk of worsening was roughly halved compared to matched controls (Taipale et al., 2026).
A systematic review of GLP-1 psychiatric effects found modest potential antidepressant effects, improvements in emotional and restrained eating patterns, and quality-of-life gains that appeared partly independent of weight loss itself (Sa et al., 2025).
Why might GLP-1 medications improve mood? Several mechanisms have been proposed. The reduction in "food noise" — the constant intrusive thoughts about eating — removes a significant source of psychological distress for many people. Weight loss itself improves self-esteem and social functioning. Better blood sugar control stabilises energy and mood throughout the day. And preclinical research suggests semaglutide may directly reduce neuroinflammation and modulate the gut-brain axis in ways that attenuate anxiety and depressive behaviours (de Paiva et al., 2024).
The balanced picture
A thorough analysis of the global VigiBase data showed mixed results for suicidality: while some signals for suicidal ideation appeared, signals for actual suicide attempts and completed suicides were not consistently elevated — and in some analyses were reduced (McIntyre et al., 2025). Real-world cohort studies found that GLP-1 medications were not consistently associated with increased suicidality (Valentino et al., 2025).
One study did find a higher reported risk of psychiatric disorders among GLP-1 users in a large obesity cohort — but the authors noted significant limitations, including the observational design and potential confounding from the underlying conditions being treated (Kornelius et al., 2024).
The FDA and EMA, after investigating the signals, found no clear causal link and have adjusted their positions accordingly.
What this means for you
If you're considering a GLP-1 medication and you have a history of depression, anxiety, or other mental health conditions — don't let the headlines scare you away from a conversation with your doctor. The clinical trial data is reassuring. The emerging real-world data suggests potential benefits for mental health, not just risks.
But monitoring matters. Pay attention to your mood, especially during the first few months and during dose changes. Let your doctor know about any history of depression, anxiety, or suicidal thoughts before starting. Have a support system in place — whether that's a therapist, a trusted friend, or a GP who checks in regularly.
If you notice persistent low mood, increased anxiety, withdrawal from activities you normally enjoy, or any thoughts of self-harm — contact your healthcare provider promptly. These medications are not known to cause these issues at meaningful rates, but you are a person, not a statistic. Your individual experience matters more than any trial average.
And if you experience the opposite — if the food noise quiets, the obsessive eating thoughts recede, and you feel mentally lighter for the first time in years — know that the research increasingly supports that experience too. For many people, that psychological relief is the most valued effect of these medications, even more than the weight loss itself.
Key Studies & References
We base this guide on the strongest available peer-reviewed research so you can see exactly where the information comes from. Here are the most relevant and impactful studies we referenced:
-
Wadden et al. (2024) — Dedicated post-hoc psychiatric safety analysis of the STEP 1, 2, 3, and 5 semaglutide trials, finding no increased risk of depression or suicidal ideation, with a small reduction in depressive symptoms compared to placebo. The strongest controlled evidence available. Read the full analysis in JAMA Internal Medicine
-
Taipale et al. (2026) — Published in The Lancet Psychiatry, this study found that people with existing depression or anxiety who started semaglutide had a substantially lower risk of their mental illness worsening (adjusted hazard ratio 0.58), suggesting potential protective effects. Read the study in The Lancet Psychiatry
-
Tobaiqy et al. (2024) — Analysis of the EudraVigilance database showing psychiatric adverse events account for only 1.18% of total GLP-1 reports, with depression (50.3%), anxiety (38.7%), and suicidal ideation (19.6%) being the most commonly reported psychiatric events. Read the analysis on PubMed
-
Sa et al. (2025) — Systematic review finding modest potential antidepressant effects of GLP-1 medications, improvements in emotional eating patterns, and quality-of-life gains that appear partly independent of weight loss itself. Read the systematic review on PMC
-
de Paiva et al. (2024) — Preclinical study showing semaglutide attenuated anxiety and depressive behaviours in a mouse model of type 2 diabetes by reducing neuroinflammation and modulating the gut-brain axis — helping explain the mechanisms behind mood improvements. Read the study on PubMed
-
McIntyre et al. (2025) — Global VigiBase analysis showing mixed signals for suicidality: while suicidal ideation reports appeared in some analyses, signals for actual suicide attempts and completed suicides were not consistently elevated. Read the analysis on PubMed
These studies reveal a nuanced picture: controlled clinical trials are reassuring, emerging data suggests potential mood benefits, and post-marketing signals — while worth monitoring — have not established a causal link between GLP-1 medications and psychiatric harm.
Medical Disclaimer: If you experience persistent low mood, increased anxiety, or any thoughts of self-harm while on GLP-1 medications, contact your healthcare provider promptly. This guide is for informational purposes only.